Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast for Insulin Sensitivity in Prediabetes
NCT01862029Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- May 2013
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of roflumilast in prediabetes, sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Change in Insulin Sensitivity at 6 weeks. Started May 2013; status: completed.
02
Drugs
roflumilast
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT01862029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01862029.